Cargando…

Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation

Non-small-cell lung cancer (NSCLC) cell lines vary in their sensitivity to glutaminase inhibitors, so it is important to identify the metabolic assets underling their efficacy in cancer cells. Even though specific genetic lesions such as in KRAS and LKB1 have been associated with reliance on glutami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caiola, Elisa, Colombo, Marika, Sestito, Giovanna, Lupi, Monica, Marabese, Mirko, Pastorelli, Roberta, Broggini, Massimo, Brunelli, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465377/ https://www.ncbi.nlm.nih.gov/pubmed/32718002 http://dx.doi.org/10.3390/cells9081766

Ejemplares similares

Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS
por: Caiola, Elisa, et al.
Publicado: (2016)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)
por: Colombo, Marika, et al.
Publicado: (2022)

LKB1: Can We Target an Hidden Target? Focus on NSCLC
por: Ndembe, Gloriana, et al.
Publicado: (2022)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
por: Caiola, Elisa, et al.
Publicado: (2018)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
por: Caiola, Elisa, et al.
Publicado: (2015)

Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
por: Sabatino, Maria Antonietta, et al.
Publicado: (2010)

It’s Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC?
por: Caiola, Elisa, et al.
Publicado: (2020)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells
por: Iezzi, Alice, et al.
Publicado: (2018)

Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
por: Alvisi, Maria Francesca, et al.
Publicado: (2020)

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
por: Ganzinelli, Monica, et al.
Publicado: (2015)

Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX()
por: Iezzi, Alice, et al.
Publicado: (2016)

The Systemic Alterations of Lipids, Alanine-Glucose Cycle and Inter-Organ Amino Acid Metabolism in Swine Model Confirms the Role of Liver in Early Phase of Septic Shock
por: Ferrario, Manuela, et al.
Publicado: (2019)

Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC
por: Lee, Jae-Seon, et al.
Publicado: (2016)

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
por: Marabese, Mirko, et al.
Publicado: (2015)

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
por: Ganzinelli, M., et al.
Publicado: (2021)

TNF-α promotes extracellular vesicle release in mouse astrocytes through glutaminase
por: Wang, Kaizhe, et al.
Publicado: (2017)

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
por: Vernieri, Claudio, et al.
Publicado: (2020)

Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis
por: Pasetto, Laura, et al.
Publicado: (2021)

Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss
por: Zhu, Xianbing, et al.
Publicado: (2023)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

Plasmatic Hippuric Acid as a Hallmark of Frailty in an Italian Cohort: The Mediation Effect of Fruit–Vegetable Intake
por: Brunelli, Laura, et al.
Publicado: (2021)

The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy
por: Lukey, Michael J., et al.
Publicado: (2016)

Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer
por: Udupa, Sunag, et al.
Publicado: (2019)

Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome
por: Khoury, Elizabeth Smith, et al.
Publicado: (2020)

Q-ing tumor glutaminase therapy
por: Stine, Zachary E., et al.
Publicado: (2015)

Governing glutaminolysis by regulation of glutaminase succinylation
por: Ma, Qingxia, et al.
Publicado: (2021)

The Role of Glutamine and Glutaminase in Pulmonary Hypertension
por: Wang, Shang, et al.
Publicado: (2022)

Targeting glutaminase to starve lymphoma cells
por: Dumontet, Charles
Publicado: (2022)

Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies
por: Mendogni, Paolo, et al.
Publicado: (2022)

Metabolic modulation of neurogenesis: Role of glutaminase-2
por: Salomoni, Paolo
Publicado: (2014)

Targeting hepatic glutaminase activity to ameliorate hyperglycemia
por: Miller, Russell A., et al.
Publicado: (2018)

Safety assessment of glutaminase from Aspergillus niger
por: Vo, Trung Duc, et al.
Publicado: (2020)

Glutaminase inhibition in renal cell carcinoma therapy
por: Raczka, Aleksandra M., et al.
Publicado: (2019)

Identification and characterization of a novel glutaminase inhibitor
por: Cederkvist, Henning, et al.
Publicado: (2021)

Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate
por: Wu, Beiqing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6c98cj0f1bmvri3ou7ra46nhh6